| 【Company Research】ZTO Express (2057 HK) – Volume growth to remain the top priority |
| 【Company Research】ZTO Express (ZTO US) – Volume growth to remain the top priority |
| 【Company Research】Jinxin Fertility (1951 HK) – Enhancing leading position by strong organic growth and efficient M&As |
| 【Company Research】Bilibili (BILI US) – 3Q20 beat on topline and guidance |
| 【Company Research】JOYY Inc. (YY US) – All in Bigo with YY Live sale |
| 【Company Research】FinVolution (FINV US) – 3Q20 earnings beat on asset quality recovery |
| 【Company Research】Baidu (BIDU US) – Solid 3Q20; Acquiring YY Live to bring synergy |
| 【Company Research】Dongfeng Motor (489 HK) – Strong 3Q results beat estimates |
| 【Company Research】I-Mab BioPharma (IMAB US) – Lemzoparlimab, a highly differentiated anti-CD47 mAb with superior safety and efficacy |
| 【Company Research】AAC Technologies (2018 HK) – 3Q20 another miss; Optics likely to improve but hard to move the needle |
Address: 45th & 46th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong
Telephone: （852）3900 0888 Fax:（852）3761 8788
Copyright © 2019-2026 CMB International Capital Corporation Limited. All rights reserved.
